This mechanism likely explains why t-MNs have a higher incidence of TP53 variants and tend to be more aggressive and less responsive to treatment compared to de novo myeloid neoplasms (Baranwal et al., 2022; Fianchi et al., 2018). The gene discussed is TP53; the disease is myeloid neoplasm.